Field Medical | $35,000,000 | (Jul 2, 2025)
Syntis Bio | $38,000,000 | (Jul 2, 2025)
Deeto | $12,500,000 | (Jul 2, 2025)
ImmuneWalk Therapeutics
United States
- Pearl River, New York
- 08/05/2025
- Seed
- $7,000,000
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. Our Monocyte Targeting Technology (MTT) is designed to selectively block the migration (`walking`) of monocytes from the blood stream into inflamed tissues. Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, we are advancing IW-601 to a Ph1 clinical trial.
- Industry Biotechnology Research
- Website https://immunewalk.com/
- LinkedIn https://www.linkedin.com/company/immunewalk-therapeutics/
Talon.One | $135,000,000 | (Jul 2, 2025)
Bonx | $8,600,000 | (Jul 2, 2025)
Civ Robotics | $7,500,000 | (Jul 2, 2025)
Metafide | $3,275,000 | (Jul 2, 2025)
Genesis AI | $105,000,000 | (Jul 2, 2025)
Emerald AI | $24,500,000 | (Jul 2, 2025)
zango | $4,800,000 | (Jul 2, 2025)
Clearspeed | $60,000,000 | (Jul 1, 2025)
Foresight(US) | $5,500,000 | (Jul 1, 2025)